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ABSTRACT 
 
              It has long been known that thyroid hormones (TH) are essential for 
normal growth, development and cell metabolism. Studies have also shown that 
topical TH application can increase epidermal cell proliferation and accelerate the 
process of cutaneous wound healing. Despite these promising results, few 
researchers have examined the mechanisms and mediators through which TH 
may exert its effects on skin cells. In this study, human fibroblasts were stimulated 
with increasing triiodothyronine (T3) concentrations. A western blot was then 
conducted on the stimulated cell samples to determine whether two key growth 
factors – epidermal growth factor (EGF) and fibroblast growth factor (FGF-7) – 
that have been implicated in wound healing were upregulated due to topical T3 
stimulation. It was found that while EGF (indirectly detected via the presence of 
the epidermal growth factor receptor (EGFR)) trended towards being upregulated 
at higher T3 concentrations, no such effect was observed with FGF-7. It was 
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therefore determined that the EGF pathway may be an important mechanism 
through which TH exerts its effects on human fibroblasts and the process of 
cutaneous wound healing. 
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 1 
INTRODUCTION 
 
Thyroid hormone biosynthesis 
        It has long been known that thyroid hormones (TH) are key players in 
growth, development and metabolism. Their effects in the body are ubiquitous 
and wide-ranging, with target organs found in the cardiovascular, neural, skin, 
and muscular systems (Wong and Schaffer, 2008). Despite its pervasive nature, 
thyroid hormone’s effects on and mechanism of action in cutaneous wound 
healing have not been extensively researched.  
       The synthesis of thyroid hormone occurs in the thyroid gland, a butterfly-
shaped organ located near the trachea (Molina, 2010). The follicular cells of the 
thyroid gland are responsible for the synthesis of thyroid hormone, and are 
bordered by thyroglobulin (TG) and glycoprotein containing cells known as the 
colloid (Barrett et al., 2012).  When the follicular cells are in the process of 
synthesizing thyroid hormone, they appear smaller, as opposed to their larger 
appearance during states of inactivity (Barrett et al., 2012).   
       The thyroid hormone (TH) itself is derived from the amino acid tyrosine, and 
its production and subsequent release in the body is tightly regulated via the 
Hypothalamic-Pituitary-Thyroid negative feedback axis (Molina, 2010).  Iodine is 
a key constituent for thyroid hormone biosynthesis, and its transport across 
thyrocytes is controlled through a system of membrane transporters (Barrett et 
al., 2012). The synthesis of thyroid hormone includes several steps and requires 
 2 
the presence of thyroid peroxidase (TPO) (Fig. 1) TPO is responsible for the 
oxidation of iodide into iodine (Fig.1).  
 
 
 
Figure 1. Biosynthesis of thyroid hormone (TH). Iodide is activated by thyroid 
peroxidase (TPO) to iodine, and it is added to a tyrosine ring to yield 
monoiodotyrosine (MIT), and diiodotyrosine (DIT). A small amount of MIT and 
DIT combine to yield triiodothyronine (T3), while the majority of DIT molecules 
combine to yield tetraiodothyronine (T4).  Figure downloaded from Molina, 2010 
at http://www.accessmedicine.com/content.aspx?aID=6169456.  
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       While the tetraiodothyronine (T4) version of the hormone is synthesized in 
larger amounts, it is the triiodothyronine (T3) variant that has greater biological 
activity (Molina, 2010).  The thyroid also synthesizes a small amount of the 
biologically inactive compound reverse triiodothyronine (rT3), although much of 
the rT3 and T3 are obtained from interconversion from T4 at the tissue level (Fig. 
2) (Molina, 2010).  
 
 
        
Figure 2. An overview of the secretion and interconversion of thyroid 
hormones (TH). The numbers refer to average daily amounts for an adult 
human. The interconversion occurs mostly at the tissue level with the help of 
deiodinases. Type I deiodinases (D1) and Type II deiodinases (D2) convert 
tetraiodothyronine (T4) to triiodothyronine (T3), while T4 is converted to reverse 
triiodothyronine (rT3) via the actions of Type III deiodinases (D3). Figure taken 
from Barrett et al., 2012 at 
http://www.accessmedicine.com/content.aspx?aID=56262695.  
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        A unique feature of thyroid hormone (TH) physiology is that the human body 
has a reserve of TH that is capable of sustaining normal bodily functions for a 
period of approximately two months (Barrett et al., 2012). Additionally, TH bound 
to proteins in the circulatory system also acts as a more immediate reserve for 
the body, as only the unbound hormones can exert their biological effects on 
cells (Barrett et al., 2012). The major protein carriers for thyroid hormones in the 
blood stream appear to be albumin, thyroxine-binding globulin (TBG), and 
transthyretin (Barrett et al., 2012). 
       In order to convert the large amount of T4 produced by the thyroid gland into 
the biologically active T3 and the inactive rT3, enzymatic molecules known as 
deiodinases are required. There are three different types of deiodinases that 
have been identified in the body, and all contain the trace element 
selenocysteine, which is essential for the enzymatic activity of the deiodinases 
(Molina, 2010).  
       Type I deiodinases (D1) – present mostly in the liver, kidney and thyroid – 
convert T4 to T3 (Molina, 2010).  Type II deiodinases (D2) also convert T4 to T3, 
and are normally found in the pituitary gland, cardiovascular and skeletal muscle 
system, brain and thyroid (Molina, 2010).  D2 is also known to play an essential 
role in the pituitary gland as part of the Hypothalamic-Pituitary-Thyroid negative 
feedback axis (Molina, 2010).  Type III deiodinases (D3) convert T4 to rT3, and 
have been found in the placenta, brain and skin (Molina, 2010).   
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Thyroid hormone regulation 
       The rate of production of thyroid hormones (TH) is tightly regulated via the 
Hypothalamic-Pituitary-Thyroid negative feedback axis (Fig.3). In essence, the 
hypothalamus secretes an entity known as the thyrotropin releasing hormone 
(TRH), which directly stimulates the thyrotropes in the anterior pituitary gland to 
release thyroid stimulating hormone (TSH). The TSH travels in the circulatory 
system to reach the thyroid gland, where it stimulates the thyroid follicles to 
produce the thyroid hormones T4, T3 and rT3 (Barrett et al., 2012). 
       Much of the negative feedback depends on the restriction of TSH production, 
effectively shutting down the communication between the anterior pituitary and 
thyroid gland (Molina, 2010). High amounts of unbound T4 and T3 act to inhibit 
the release of TSH from the anterior pituitary, as do certain other signaling 
molecules released during physiological states of stress (Barrett et al., 2012).  
       Structurally, TSH consists of an α-subunit (identical to the α-subunit found in 
the follicle stimulating hormone (FSH), luteinizing hormone (LH), and the human 
chorionic gonadotropin hormone (hCG)), and a distinct β-subunit which accounts 
for its physiologic activity (Sathananthan et al., 2008). TSH acts on the thyroid via 
a G-protein – linked receptor to stimulate the production of thyroid hormones in 
the follicular cells (Sathananthan et al., 2008). 
       It is interesting to note that in the absence of the pituitary gland and 
endogenous TSH production, the thyroid gland starts to degenerate (Barrett et 
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al., 2012). In such a scenario, the biological activity of the thyroid gland can be 
restored via the exogenous administration of TSH (Barrett et al., 2012).  
 
 
Figure 3. The Hypothalamic-Pituitary-Thyroid negative feedback axis. 
Thyrotropin releasing hormone (TRH) produced by the hypothalamus stimulates 
the anterior pituitary gland to release thyroid stimulating hormone (TSH). TSH 
stimulates the thyroid gland to produce the thyroid hormones (TH), 
tetraiodothyronine (T4) and triiodothyronine (T3). High levels of free T4 and T3 
subsequently act as negative feedback regulators to inhibit the release of TSH 
from the thyrotropes in the anterior pituitary. Figure downloaded from Molina, 
2010 at http://www.accessmedicine.com/content.aspx?aID=6169456.  
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Thyroid Hormone mechanism of action 
       Given the lipophillicity of the thyroid hormones (TH), their physiological 
effects are mediated intracellularly, and the hormone is thought to enter the cell 
via plasma membrane carrier proteins (Molina, 2010) (Fig.4).  Once inside the 
cells, the hormone binds to TH specific nuclear receptors and Thyroid Hormone 
Response Elements (TRE), and thus affects the transcriptional regulation of 
select genes (Molina, 2010) (Fig.4). Thyroid hormone receptors have been 
identified in a variety of tissues including skin fibroblasts, hair follicles, and 
epidermal keratinocytes (Safer et al., 2001).  
 
Figure 4. The biological effects of thyroid hormone are regulated 
intracellularly. Plasma membrane receptors allow tetraiodothyronine (T4) and 
triiodothyronine (T3) to enter the cell, and type I deiodinases (D1) convert T4 to T3 
in the cell membrane. T3 then mediates its effects in the nucleus by binding to TH 
nuclear receptors and Thyroid Hormone Response Elements (TRE), thereby 
producing the desired gene product. Figure downloaded from Molina, 2010 at 
http://www.accessmedicine.com/content.aspx?aID=6169456. 
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Thyroid hormone and wound healing   
         Prior to the demonstration that the addition of thyroid hormone (TH) to 
human skin cultures increased epidermal cell proliferation, TH’s cutaneous 
effects have long been observed in thyroid related pathologies (Safer et al., 
2003). When there is a lack of TH synthesis in the body leading to 
hypothyroidism, the epidermis is noticeably dry; while in states of high TH 
synthesis leading to hyperthyroidism, the epidermis is observed to be thinner 
than normal (Safer, 2012). The presence of thyroid hormone receptors (TR) in 
the skin has also been demonstrated, as has the expression of deiodinases 
(Safer, 2012). Despite these findings that indicate that TH has an effect on skin 
cells and their proliferation, very little data exists examining whether TH could be 
used in a topical manner to accelerate cutaneous wound healing.  
       A few studies conducted by Safer et al. have demonstrated that topical 
thyroid hormone application can increase epidermal cell growth and thus 
accelerate wound healing in mice (Fig. 5) (Safer et al., 2004; and Safer et al., 
2005). Using Real-Time Polymerase Chain Reaction (RT-PCR), the investigators 
determined that keratinocyte genes in the epidermis were upregulated in skin 
cells stimulated by thyroid hormone when compared with cells that were not 
stimulated (Safer et al., 2004). Keratin is an important constituent of the 
epidermis, and accelerating its expression can aid in improving wound healing 
(Safer et al., 2004).  
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       Additionally, Safer et al. have also shown in vivo that daily topical application 
of thyroid hormone on the skin of wounded mice resulted in a 58% increase in 
wound healing when compared to wounded mice that were not given any topical 
thyroid hormone (Fig. 5) (Safer et al., 2005). Their data indicated that epidermal 
keratin 6 protein expression increased in vivo with increasing thyroid hormone 
(TH) concentration (Safer et al., 2005). Epidermal keratin 6 is an important 
wound repair protein and its upregulation by TH indicates that topical TH 
application can potentially be used in cases of slow healing wounds (Safer et al., 
2005). 
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Figure 5. The effect of topical thyroid hormone application on wound 
healing in mice. A and B indicate wounds at the start and finish of the 
experimental period, respectively. The wounds to the left of each panel received 
no thyroid hormone, while the ones pictured to the right received a daily dose of 
triiodothyronine (T3). C indicated that there was significant reduction in the 
wounds treated by T3 at the end of the study. Figure taken from Safer, et al. 
2005.  
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An overview of wound healing 
       The efficient and proper closure of cutaneous wounds is essential to 
maintaining the body’s microenvironment. As the largest organ in the body, the 
skin serves an essential role in preventing the entry of environmental 
pathological agents into cells. The improper or slow healing of cutaneous wounds 
can lead to the dysfunction of key bodily process and result in severe morbidity 
and even mortality (Singer and Clark, 1999). In 2009, Sen et al. estimated that 
approximately US$25 billion is spent every year in the United States due to 
complications arising from slow healing wounds (Sen et al., 2009). This figure is 
only expected to rise as conditions that impair cutaneous wound healing – such 
as diabetes – increase in prevalence (Sen et al., 2009). There is thus a critical 
need to find inexpensive and novel therapies that can accelerate the process of 
wound healing.  
          In order to comprehend the events and mediators involved in cutaneous 
wound healing, it is essential to have a basic understanding of the structure of 
the skin. The skin is composed of three major layers known as the epidermis, the 
dermis, and the subcutaneous adipose tissue (Mihm et al., 2012). The major cell 
type found in the epidermis is the keratinocyte, while an extracellular matrix 
consisting of collagen and other elastic fibers forms a large portion of the dermis 
(Mihm et al., 2012). There are also several glands and hair follicles that can be 
found entrenched into the three cutaneous tissues (Mihm et al., 2012). 
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        The process of cutaneous wound healing itself is a complicated and multi-
step process that involves the coordinated efforts of several biological mediators 
and cell types (Fig. 6). The end goal is to restore the proper functioning and 
structure of the skin, and to close off the injured area to pathological agents 
found in the environment. Cutaneous wound healing can broadly be divided into 
three key phases known as the inflammatory phase, the granulation tissue 
formation phase, and the tissue remodeling phase (Fig. 6) (Singer and Clark, 
1999). While the phases do begin in a sequential order, they also overlap and 
there are no clear temporal markers separating one phase from another (Fig. 6) 
(Singer and Clark, 1999). 
        The inflammatory phase begins immediately following tissue injury. A fibrin 
clot is formed to curb any bleeding in the area, and the clot also serves as a 
provisional mesh framework that cells can later use to move into the wounded 
region (Barbul, 2010). A fundamental hallmark of the inflammatory phase is the 
presence of polymorphonuclear leukocytes (PMNs) – better known as 
neutrophils – in the wounded area (Fig.7) (Barbul, 2010). The neutrophils act as 
a first line of defense and function in bacterial phagocytosis and the removal of 
dysfunctional cell remains (Barbul, 2010).  
       The platelets present in the blood clot also release several chemical 
mediators – such as epidermal growth factor (EGF), transforming growth factor 
beta (TGF-β), and platelet-derived growth factor (PDGF) – that serve to recruit 
fibroblasts and monocyte derived macrophages to the wound (Fig. 7) (Barbul, 
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2010). Macrophages are essential for proper bacterial clearance, and the release 
of chemical mediators and growth factors needed to recruit cells (e.g. endothelial 
cells and fibroblasts) that are vital for proper healing to occur (Fig.7) (Barbul, 
2010). 
 
Figure 6. The phases of cutaneous wound healing. The top panel serves to 
indicate the overlap between the different phases of wound healing, with the 
timescale beginning in units of days followed by months. The middle panel shows 
the key cells involved in each phase, while the bottom panel shows the major 
structural proteins deposited in each phase of healing. Figure downloaded from 
Barbul, 2010 at http://www.accessmedicine.com/content.aspx?aID=5013857. 
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        The granulation tissue formation or proliferation phase of cutaneous wound 
healing overlaps with the tail end of the inflammation phase, and has been 
observed to occur approximately 4 days after injury (Fig. 6) (Barbul, 2010). The 
key cell types involved in this phase are the fibroblast cells – which are needed 
for the formation of the extracellular matrix – and endothelial cells, which are 
essential to the process of angiogenesis (Barbul, 2010). Both fibroblast and 
endothelial cells are recruited to the wound site by growth factors and cytokines 
secreted by the cells in the inflammatory phase (Barbul, 2010). The matrix 
synthesized by the activated fibroblasts consists mainly of collagen types I and 
III, and proteoglycans, and it is needed for subsequent wound closure and scar 
formation (Barbul, 2010). 
       The final phase of wound healing – known as the extracellular matrix 
remodeling phase – consists of amending the previously laid down granulation 
tissue collagen matrix to form a more permanent scar (Singer and Clark, 1999). 
This phase overlaps with the granulation tissue formation phase and can last 
from a period of days to months (Fig. 6) (Singer and Clark, 1999). Remodeling of 
the previously laid down ECM takes place due to the actions of enzymatic matrix 
metalloproteinases secreted by macrophages and fibroblasts (Singer and Clark, 
1999). Matrix metalloproteinases break down collagen fibers, and the final 
product of remodeling represents an equilibrium between proper collagen 
degradation and collagen production (Barbul, 2010). The proliferation of epithelial 
cells to replace those lost to injury also continues in this phase of cutaneous 
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wound healing, and EGF, PDGF, and keratinocyte growth factor (KGF) have 
been thought to play an important role in this process (Barbul, 2010). 
 
 
Figure 7. Key mediators in cutaneous wound healing as observed 3 days 
after injury. The inflammatory phase of wound healing involves several 
cytokines and growth factors that work in a coordinated fashion to repair a 
wounded area. Shown above are the functional manifestations of the fibroblast 
growth factor (FGF), insulin-like growth factor (IGF), keratinocyte growth factor 
(KGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), 
and vascular endothelial growth factor (VEGF). Figure taken from Singer and 
Clark, 1999.  
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Growth factors and thyroid hormone induced wound healing  
       Effective cutaneous wound healing involves a highly choreographed 
sequence of growth factor activation (Fig. 7). There are several growth factors 
that have been identified in wound healing, and each one plays a specific role in 
repairing the wound and restoring the integrity of the skin  (Table 1). It is 
therefore not unreasonable to postulate that thyroid hormones (TH) may exert 
their effects on wound healing by upregulating or mediating the effects of some 
of these growth factors, and for the purposes of this study, we will be focusing on 
the epidermal growth factor (EGF), and the keratinocyte growth factor (KGF) 
(Fisher et al., 1982).  
 
Epidermal growth factor (EGF) 
       In 1983, Hoath et al. conducted a study to examine the effects of TH 
application on EGF concentration in neonatal mouse skin (Hoath et al., 1983). 
EGF is normally secreted by platelets, macrophages, and fibroblasts cells, and 
plays a critical role in promoting epithelial cell proliferation and migration in 
tissues following injury (Yu et al., 2010).  
       Hoath et al. found that daily injections of T4 and T3 resulted in a dose-
dependent increase in EGF concentrations in the neonatal mouse skin samples, 
indicating that TH effects on skin could be mediated via the EGF pathway (Hoath 
et al., 1983). The stimulation of the mouse skin samples with 0.2 µg and 0.1 µg 
of T3 resulted in EGF concentrations rising from 152 ± 11 pg/mg protein in the 
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control population to 408 ± 57 pg/mg protein (for 0.2 µg T3 application) and 575 ± 
61 pg/mg protein (for 1.0 µg T3 application) in the EGF treated population (Hoath 
et al., 1983). The researchers also demonstrated that the biologically inactive rT3 
had no noticeable effect on EGF concentration in the neonatal mouse skin 
samples (Hoath et al., 1983).     
       Additionally, in a randomized and double-blind clinical trial, Brown et al. 
showed that topical application of EGF on wounded human skin resulted in a 
decrease in the time required for the skin to heal by up to 50 percent by one day, 
and heal by up to 100 percent by 1.5 days (Brown et al., 1989). Despite data in 
support of EGF’s potential role in accelerating wound healing, there has been a 
dearth of data examining its use in therapeutic applications.  
       EGF is part of a family of proteins that includes transforming growth factor 
alpha (TGF-α), and the heparin-binding EGF-like growth factor (HB-EGF) (Yu et 
al., 2010). TGF-α and HB-EGF are also important in wound healing and are 
primarily secreted by keratinocyte cells (Yu et al., 2010). All three ligands exert 
their effects on cells by binding to the receptor tyrosine kinase (RTK) epidermal 
growth factor receptor (EGFR).  
       EGFR is a 170-kDa transmembrane glycoprotein, and it is known to activate 
several signaling cascades that mediate the cutaneous wound healing effects of 
the EGFR ligands (Fig. 8) (Koppikar and Grandis, 2008). EGFR is comprised of 
an extracellular ligand binding domain, a transmembrane domain, and a catalytic 
cytoplasmic domain (Fig. 8) (Eswarakumar et al., 2005). In this study we will 
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measure EGFR upregulation as a proxy for EGF production by TH stimulated 
fibroblasts.  
Table 1. Growth factors involved in cutaneous wound healing. 
 
Growth Factor Production Known Effects 
1. Epidermal 
Growth Factor 
(EGF) 
Platelets, 
macrophages, 
fibroblasts 
Stimulates fibroblasts to secrete collagenase to degrade the matrix 
during the remodeling phase. Stimulates keratinocyte and 
fibroblast proliferation. May reduce healing time when applied 
topically. 
2. Transforming 
Growth Factor 
Platelets, 
macrophages, 
lymphocytes, 
hepatocytes 
TGF-a: Mitogenic and chemotactic for keratinocytes and 
fibroblasts 
TGF-b1 and TGF-b2: Promotes angiogenesis, up-regulates 
collagen production and inhibits degradation, promotes 
chemoattraction of inflammatory cells. 
TGF-b3 (antagonist to TGF-b1 and b2): Has been found in high 
levels in fetal scarless wound healing and has promoted scarless 
healing in adults experimentally when TGF-b1 and TGF-b2 are 
suppressed.  
3. Vascular 
Endothelial 
Growth Factor 
(VEGF) 
Endothelial 
cells 
Promotes angiogenesis during tissue hypoxia. 
4. Fibroblast 
Growth Factor 
(FGF) 
Macrophages, 
mast cells, T-
lymphocytes 
Promotes angiogenesis, granulation, and epithelialization via 
endothelial cell, fibroblast, and keratinocyte migration, 
respectively. 
 
5. Platelet-Derived 
Growth Factor 
(PDGF) 
Platelets, 
macrophages, 
and 
endothelial 
cells 
Attracts macrophages and fibroblasts to zone of injury. Promotes 
collagen and proteoglycan synthesis. 
8. Keratinocyte 
growth factor 
Fibroblasts Stimulates keratinocyte migration, differentiation, and 
proliferation. 
 
The table represents only a partial list of the growth factors implicated in wound 
healing. Figure downloaded and amended from Gabriel et al., 2011 at 
http://emedicine.medscape.com/article/1298196-overview#aw2aab6b4. 
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Figure 8. The effects of ligand binding on the epidermal growth factor 
receptor (EGFR). Shown above are the major signaling cascades affected by 
the activation of EGFR, namely the mitogen-activated protein kinase (MAPK) 
pathway, the phosphatidylinositol-3-OH kinase (PI3K/Akt) pathway, the 
phospholipase Cγ (PLCγ) pathway, and the signal transducers and activators of 
transcription (STAT) pathways. Figure downloaded from Koppikar and Grandis, 
2008 at http://link.springer.com.ezproxy.bu.edu/chapter/10.1007/978-1-59745-
356-1_6. 
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Keratinocyte growth factor (KGF) 
 
       KGF, also known as fibroblast growth factor-7 (FGF-7), is 28 kDa protein 
that is part of a family of growth factors that are involved in stimulating the 
proliferation and differentiation of a variety of cell types (Werner, 1998). KGF in 
particular acts on epithelial cells, and in the process of wound healing it is 
secreted by fibroblasts stimulated by cytokines and growth factors released by 
platelets, neutrophils, and macrophages (Fig. 9) (Werner, 1998).  
       There are four known RTK based fibroblast growth factor receptors (FGFR), 
and they are generally referred to as FGFR1, FGFR2, FGFR3, and FGFR4 
(Werner, 1998). KGF is known to only bind to the IIIb isoform of the FGFR2 
receptor (Werner, 1998). For successful binding to occur between the fibroblast 
growth factors and their receptors, heparin sulphate oligosaccharides and 
cycsteine-rich FGF-binding proteins are needed (Werner, 1998). 
       There have been several studies describing the essential role that KGF 
plays during cutaneous wound healing. It is know that the IIIb isoform of the 
FGFR2 receptor is present in the epidermal layer of skin (Werner, 1998). In 
1992, Werner et al. demonstrated that there was a 160-fold increase in KGF 
mRNA immediately following a cutaneous wound, indicating that dermally 
secreted KGF might play an essential role in the proliferation of keratinocytes in 
the epidermis during the granulation tissue formation and ECM remodeling phase 
of wound healing (Werner et al., 1992).  
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       Additionally, it was found that the exogenous application of KGF on 
cutaneous wounds in pigs caused an increase in epithelial cell proliferation, and 
the PDGF secreted by platelets was essential in stimulating fibroblasts to secrete 
KGF in response to a cutaneous wound  (Werner, 1998). There have also been 
in vivo studies conducted in mice that have demonstrated that the lack of KGF 
leads to decreased keratinocyte proliferation and angiogenesis (Peng et al., 
2011). Given such data, it is vital that we understand whether KGF secretion by 
fibroblasts can be upregulated by the topical application of TH, so that we can 
have an inexpensive method with which we can stimulate KGF production in 
fibroblasts and accelerate wound healing.  
 
 
 
 
        
 
 
 
 
 
 
Figure 9. The release of keratinocyte growth factor (KGF) from fibroblasts 
is mediated by cytokines released by macrophages, platelets and 
polymorphonuclear leukocytes (PMNs). The major stimulators for KGF 
release from fibroblasts include platelet-derived growth factor (PDGF), 
transforming growth factor alpha (TGF–α), tumor necrosis factor alpha (TNF– α), 
and interleukin–1 (IL–1). Glucocorticoids are known to inhibit the release of KGF. 
Figure taken from Werner, 1998.  
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Objectives 
       The cutaneous effects of TH have long been observed in cases of thyroid 
dysfunction, and recent studies have also demonstrated the potential therapeutic 
role topical TH application may play in accelerating cutaneous wound healing 
(Safer et al., 2005, and Safer et al, 2004). Despite the promising data observed 
in these studies, few researchers have attempted to characterize the 
mechanisms through which TH may exert its effects on wound closure.  
       The goal of this study is to determine the effects of TH stimulation on growth 
factors released by fibroblasts cells. In particular, we will examine whether EGF 
and KGF secretion is upregulated in a dose-dependent manner when fibroblasts 
are stimulated with increasing amounts of TH. Both EGF and KGF are secreted 
by fibroblasts when they are stimulated by cytokines released by platelets, 
macrophages, and neutrophils during wound healing, and they are critical to 
epidermal proliferation (Fig.7 and Fig. 9). Given the essential nature of their roles 
in skin regeneration, it is plausible that TH could exert its effects on cutaneous 
wound healing by upregulating the expression of EGF and KGF.  
       We will conduct western blots on fibroblast cells stimulated with increasing 
concentrations of T3, in order to ascertain EGF (indirectly measured via the 
expression of EGFR) and KGF upregulation. If the expression of EGF or KGF is 
enhanced in TH stimulated fibroblasts, we can have a better idea of the biological 
pathways though which TH mediates its effects on wound healing.  
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MATERIALS AND METHODS 
 
Cell Culture 
       Human dermal fibroblasts were used in all experimental procedures, and the 
fibroblasts were grown in a monolayer to approximately 80% confluence before 
use. Overgrown cells were not used in the experiments.  Sterile petri dishes were 
used to grow the cells and all cell handling took place under a sterile cell culture 
approved hood.  
       Cell culture media was prepared using high glucose HEPES Dulbecco’s 
Modified Eagles Medium (DMEM), 5% charcoal stripped Fetal Bovine Serum 
(FBS), and 1% antibiotic. Before passage or removal from the petri dish, cells 
were washed with Ethylenediaminetetraacetic acid (EDTA) and dislodged from 
the petri dish using cell culture grade trypsin. In order to enable the cells to come 
off easily from the plates, they were incubated with pre-warmed Trypsin at 37° C 
for no more than 5 – 10 minutes. The media was changed roughly once every 3 
days or as necessary, and the cells were grown at 37° C and 5% CO2.  
       Cells were maintained and used in experimental procedures for no more 
than 3 – 4 weeks at a time. This was done to avoid complication of the data due 
to anomalies resulting from older cells, and to also prevent any kind of 
contamination from clouding the experimental outcome.  In order to pass and 
maintain the cell line, a 1/0 dilution of cells to media was used.  
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Dosing the fibroblasts 
       A 1mM T3 stock solution was prepared under sterile conditions by adding 6.5 
mg of T3 (Sigma-Aldrich, catalog number – T67407) to 40ul of 5M NaOH, and 
then diluting the solution with distilled water to give a final stock volume of 10ml. 
The stock solution was refrigerated at 4° C and was kept protected from light. 
The solution was made fresh for every new batch of fibroblasts. 
       When the cells had reached the desired confluency and were ready to be 
dosed with T3, the 1mM T3 stock solution was diluted in DMEM to yield the 
following T3 concentrations: 10-7M T3 and 10-8 M T3.  A serial dilution of the 1mM 
T3 stock solution was conducted to yield the T3 concentrations, and the total 
volume in the petri dishes was maintained at 10ml.  
       The fibroblasts were dosed with the varying T3 concentrations approximately 
16 – 18 hours before they were lysed. Additionally, one plate of the cells was not 
dosed and was used as an experimental control.  
 
Cell lysis 
       Lysis buffer was made by adding 1 protease inhibitor cocktail tablet (Pierce 
Biotechnology Ltd., catalog number – 78410) to 10ml of 
Radioimmunoprecipitation (RIPA) lysis buffer (Santa Cruz Biotechnology Inc., 
catalog number – sc-24948). The buffer was kept on ice when used immediately 
or stored at -4° C for future use.  
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       Fibroblasts stimulated with T3 were washed with EDTA and removed from 
the plate using trypsin and a sterile cell scraper. The cells were spun down at 
1200 RPM for 5 minutes or until a visible cell pellet was formed. The supernatant 
was removed and 250ul of lysis buffer was added to each tube. Cells were 
resuspended in the lysis buffer and placed on ice for approximately 15 – 20 
minutes. The cell suspension was subsequently spun down for 10 minutes at 
4°C, and the supernatant was collected and stored at -80° C until experimental 
use.  
 
Western Blot solutions  
       NuPAGE® MES SDS 20X running buffer (Invitrogen Life Technologies, 
catalog number – NP0002) was diluted to 1X for use. 10X transfer buffer stock 
was prepared by adding 30.3g of Tris Base and 114g of glycine to 1L of distilled 
water. A 1X stock of the transfer buffer was prepared on the day of the 
experiment by adding 100ml of 10X transfer buffer stock to 200ml of methanol, 
and bringing the volume up to 1L with distilled water.  
       An Amersham ECL detection solution (GE Healthcare, catalog number – 
RPN2132) was used to detect the proteins after the western blotting procedure. 
Detection solution was assembled immediately prior to membrane exposure as 
per kit instructions.  
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Western Blot antibodies 
       The primary antibodies used in the experimental procedures included a 28 
kDa rabbit polyclonal IgG FGF-7 (H-73) antibody (Santa Cruz Biotechnology Inc., 
catalog number – sc-7882), a 170 kDa rabbit polyclonal IgG EGFR (1005) 
antibody (Santa Cruz Biotechnology Inc., catalog number – sc-03), and a 45 kDa 
mouse monoclonal β-Actin antibody (Cell Signaling Technology, catalog number 
– 8H10D10).  The FGF-7 and EGFR primary antibodies were diluted 1:500 in 5% 
BSA/Tris-Buffered Saline and Tween-20 (TBST), while the β-Actin antibody was 
diluted 1:1000 in 5% BSA/TBST.  
       The secondary antibodies used for detection were the horseradish-
peroxidase-conjugated goat anti-rabbit IgG antibody (Sigma-Aldrich, catalog 
number – A6154), and the horseradish-peroxidase-conjugated goat anti-mouse 
IgG antibody (Sigma-Aldrich, catalog number – A4416). Both secondary 
antibodies were diluted 1:1000 in 1% BSA/TBST.  
 
Western Blot procedure  
       Cell samples were prepared according to standard western blotting protocol. 
The frozen lysed fibroblasts were defrosted at room temperature. 13ul of the cell 
sample was mixed with 2ul of NuPAGE® 10X DTT/Sample reducing agent 
(Invitrogen Life Technologies, catalog number – NP0004), 5ul of NuPAGE® 4X 
LDS sample buffer (Invitrogen Life Technologies, catalog number – NP0007), 
and this mixture was heated at 70°C for 10 minutes.  Following this, NuPAGE® 
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Novex 4-12% Bis-Tris Gels (Invitrogen Life Technologies, catalog number – 
NP0322BOX) were loaded with 15ul of the treated cell samples, and 15ul of 
SeeBlue® Plus2 Pre-Stained Standard ladder (Invitrogen Life Technologies, 
catalog number – LC5925). The gels were run at 170V for approximately 35 – 40 
minutes.  
       Nitrocellulose membranes (Invitrogen Life Technologies, catalog number – 
LC2001) were used to set up the transfer cassettes, and the transfer was run at 
220mA for 50 minutes. The membrane was then removed from the transfer 
chamber and blocked for 1 hour in a 5% BSA/TBST blocking solution, which was 
made by adding 5mL of powdered BSA to 1X TBST.   
       Primary antibodies diluted in 5% BSA/TBST were added after the blocking 
period, and the membrane was allowed to incubate overnight at 4°C on a shaker. 
The membrane was washed three times with 5% BSA/TBST before the addition 
of the secondary antibody, which was diluted in 1% BSA/TBST, prepared by 
adding 10ml of 5% BSA/TBST to 50ml of TBST. The membrane was shaken in 
the secondary antibody mixture for 1 hour at room temperature.  
       Prior to the addition of the ECL detection solution, the secondary antibody 
was removed and the membrane was washed three times with 5% BSA/TBST. 
Hyperfilm ECL (GE Healthcare, catalog number – 28906835) was used to 
visualize the membrane after treatment with the ECL detection solution.  
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Results  
        The present study was conducted with the intention of understanding the 
growth factors and signalling pathways through which TH mediates its effects on 
cutaneous wound healing. Given the multiplicity of growth factors and cytokines 
implicated in wound healng, we decided to focus on EGF and KGF. Both EGF 
and KGF are strongly upregulated during injury and cutaneous wound healing, 
and function in the proliferation of epidermal cells and skin restoration. It is 
therefore plausible that TH functions in accelerating cutaneous wound healing via 
the EGF or KGF signalling pathway. 
       Human fibroblast cells were stimulated with 10-7 M T3 and 10-8 M T3. There 
was also a control set of fibroblast cells that were not stimulated by T3. The cells 
were incubated with the exogenous TH for approximately 18 hours, after which 
they were lysed and a western blot was conducted to examine whether the 
addition of TH resulted in the upregulation of EGF (as measured by the presence 
of EGFR) or KGF. β – actin was used as a loading control during the 
experiments.  
        As evidenced in Fig. 10 and Fig. 11, fibroblasts stimulated with TH trended 
towards upregulated levels of EGF but not KGF, although statistical significance 
was not observed due to the small sample size. The control cells showed a small 
amount of endogenous EGF expression, this being consistent with established 
knowledge that fibroblasts secrete EGF (Fig. 10). Addition of exogenous T3 
resulted in moderately increased expression of EGF, with the 10-7 M T3 
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stimulated cells displaying stronger EGF expression when compared to the 
control cells with no added T3, and the cells stimulated with a lower (10-8 M) 
concentration of T3 (Fig. 10). Moreover, since the β – actin expression levels 
remained consistent across all cell samples, we can be confident in the 
conclusion that stimulation with T3 does trend towards upregulating EGF 
expression in fibroblasts (Fig. 10).  
       KGF expression did not appear to be altered by exogenous T3 stimulation of 
the fibroblasts (Fig. 11). As expected, a baseline level of KGF was expressed by 
all fibroblast samples, and β – actin was again used as a loading control and was 
found to be constant across all the cells tested (Fig. 11).  
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Figure 10. Triiodothyronine (T3) stimulation of fibroblasts increases 
epidermal growth factor (EGF) expression. A. EGF expression trended 
towards increasing at higher T3 concentrations, as observed by comparison of 
band intensities. B. Representative blot. Lane 1 depicts unstimulated fibroblasts, 
lane 2 represents fibroblasts stimulated with 10-8 M T3, and lane 3 represents 
fibroblast stimulated with 10-7 M T3. As observed in lane 3, the expression of 
EGFR (170 kDa) appears to be upregulated at higher T3 concentrations. The β – 
actin loading control can be observed at 42 kDa.  
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Figure 11. Triiodothyronine (T3) stimulation of fibroblasts does not appear 
to impact keratinocyte growth factor (KGF) production. A. KGF expression 
did not seem to be affected by T3, as observed by comparison of band intensities 
B. Representative blot of fibroblast cells stimulated with T3. Lane 1 represents 
unstimulated fibroblasts, lane 2 represents fibroblasts stimulated with 10-8 M T3, 
and lane 3 represents fibroblast stimulated with 10-7 M T3. The amount of KGF 
(28 kDa) across all fibroblast cell samples did not exceed the base levels seen in 
lane 1. The β – actin loading control can be observed at 42 kDa.  
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Discussion 
       Wound healing is a tightly controlled process that involves the concerted 
efforts of several growth factors and cytokines. These chemical mediators 
function in bacterial clearance, epidermal cell proliferation, and subsequent 
wound contraction and closure. Improper or slow healing wounds can cause 
significant disruptions of cellular processes, and they represent a major drain on 
healthcare resources (Sen et al., 2009). There is therefore a need for novel and 
inexpensive therapies that can accelerate the process of wound healing.  
       Safer et al. have conducted several studies evaluating the use of topically 
applied TH in accelerating wound healing (Safer et al., 2005, Safer et al., 2004). 
While the pathways through which TH mediates its effect were not extensively 
evaluated, the data is clear in its indication that TH applied exogenously can 
accelerate the closure of wounds in vivo (Safer et al., 2005). The therapies used 
currently in hastening cutaneous wound closure are expensive since they involve 
the isolation and purification of protein mediators (Safer et al., 2005). TH can 
therefore be used as an economical means through which we can activate the 
pathways involved in wound closure and skin regeneration (Safer et al., 2005). 
       In this study we set out to evaluate whether the effects of TH on cutaneous 
wound healing are mediated via growth factors – specifically EGF and KGF. Both 
EGF and KGF are produced by dermal fibroblast cells and are significantly 
upregulated during injury. Their major function is keratinocyte cell proliferation 
and migration, and they are essential to the restoration of the epidermis following 
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a cutaneous wound. Lack of either EGF or KGR has been known to result in 
impaired wound healing (Repertinger et al., 2004 and Werner, 1998).  
        After conducting western blots on lysed control fibroblast cells and 
fibroblasts stimulated with 10-7 M T3 and 10-8 M T3, it was determined that while 
EGF production in fibroblasts appeared to be enhanced by the addition of topical 
T3, no such induction effect was observed for KGF (Fig. 10 and Fig. 11). The 
fibroblasts stimulated with the highest amount of T3 used in this experiment (10-7 
M T3) trended towards higher EGF expression when compared to control cells 
(no added T3), and fibroblasts stimulated with a lower amount of T3 (10-8 M T3).  
       This result is not entirely unexpected and confirms the data published by 
Hoath et al. (Hoath et al., 1983). Their studies indicated that the exogenous 
addition of TH to the skin of neonatal mice resulted in a surge of EGF expression 
in the tissue (Hoath et al., 1983). The researchers went on to postulate that it is 
likely that TH mediates its cutaneous effects via the major signaling pathways 
activated when EGF binds to its receptor (Fig. 8), either by increasing the 
expression of EGFR or by increasing the affinity of binding between EGF and 
EGFR (Hoath et al., 1983).  While our study did not attempt to differentiate 
between the two scenarios described in Hoath et al., future experiments with a 
larger sample size can be conducted in order to isolate the exact mechanism 
through which TH upregulates the functional manifestations of EGF.  
       Our study also found that KGF expression levels were not upregulated in 
fibroblast cells stimulated by T3. KGF levels appeared to have remained the 
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same in stimulated and unstimulated fibroblasts, leading us to postulate that T3 
does not mediate its effects on wound healing via KGF – dependent pathways.  
      This result is significant in that it allows us to understand better how T3 
functions in wound healing. KGF is essential to keratinocyte migration, 
proliferation, and differentiation; and its absence is known to result in improperly 
healed wounds (Werner et al., 1992).  It is possible that the large induction of 
EGF by T3 is sufficient to result in successful wound closure, although this must 
be furthered evaluated by conducting both in vitro and in vivo studies in samples 
devoid of KGF but stimulated with increasing T3 concentrations.  
       Additionally, in a study conducted by Brauchle et al. it was demonstrated that 
several serum growth factors expressed during wound healing could upregulate 
the expression of KGF in fibroblast cells (Brauchle et al., 1994). One of these 
growth factors was EGF, although it was found to not be as potent a stimulator of 
KGF expression as PDGF (Brauchle et al., 1994). It can then be hypothesized 
that even though T3 may not directly upregulate KGF expression in fibroblasts, it 
could function in an indirect manner by upregulating EGF, which in turn could 
stimulate KGF production. In this manner stimulation of fibroblasts with T3 can 
result in the functional effects of both EGF and KGF.  
       There is also the possibility that the amount of T3 that was used to stimulate 
the cells in our study was insignificant in rendering the upregulation of KGF 
expression. Future repetitions of this experiment should ideally include a larger 
sample size and a broader T3 concentration range to obtain statistical 
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significance, although this may be problematic as large amounts of T3 could 
potentially result in cell toxicity and death.  
       In conclusion, the present study has shown that exogenous addition of T3 to 
human fibroblast cells appears to stimulate the production of EGF, but not KGF. 
This information is critical to expanding our understanding of how T3 functions in 
accelerating wound healing, and can be applied in support of developing novel 
and inexpensive therapies that use T3 in the treatment of slow healing wounds.  
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